Cover Image
市場調查報告書

細胞分裂週期7同源體蛋白激酶:開發中產品分析

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 365750
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
細胞分裂週期7同源體蛋白激酶:開發中產品分析 Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016
出版日期: 2016年11月09日 內容資訊: 英文 32 Pages
簡介

本報告提供以細胞分裂週期7同源體蛋白激酶為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞分裂週期7同源體蛋白激酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Millennium Pharmaceuticals, Inc.
  • ProNAi Therapeutics, Inc.
  • SBI Biotech Co., Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0642TDB

Summary

Global Markets Direct's, 'Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
  • The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents 2
  • List of Tables 3
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) Overview 6
  • Therapeutics Development 7
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Stage of Development 7
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Therapy Area 8
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Indication 9
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Products Glance 10
  • Early Stage Products 10
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Companies 11
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Products under Development by Universities/Institutes 13
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Assessment 15
  • Assessment by Monotherapy/Combination Products 15
  • Assessment by Mechanism of Action 16
  • Assessment by Route of Administration 17
  • Assessment by Molecule Type 18
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development 19
  • Amgen Inc. 19
  • Millennium Pharmaceuticals Inc 20
  • ProNAi Therapeutics, Inc. 21
  • SBI Biotech Co., Ltd. 22
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles 23
  • MSK-777 - Drug Profile 23
  • Product Description 23
  • Mechanism Of Action 23
  • R&D Progress 23
  • PNT-141 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • Small Molecule to Inhibit Cdc7/ASK for Oncology - Drug Profile 25
  • Product Description 25
  • Mechanism Of Action 25
  • R&D Progress 25
  • Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile 26
  • Product Description 26
  • Mechanism Of Action 26
  • R&D Progress 26
  • Small Molecules to Inhibit CDC7 for Oncology - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • TAK-931 - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Projects 29
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products 30
  • Appendix 31
  • Methodology 31
  • Coverage 31
  • Secondary Research 31
  • Primary Research 31
  • Expert Panel Validation 31
  • Contact Us 31
  • Disclaimer 32

List of Tables

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Therapy Area, H2 2016 8
  • Number of Products under Development by Indication, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 10
  • Number of Products under Development by Companies, H2 2016 11
  • Products under Development by Companies, H2 2016 12
  • Number of Products under Investigation by Universities/Institutes, H2 2016 13
  • Products under Investigation by Universities/Institutes, H2 2016 14
  • Assessment by Monotherapy/Combination Products, H2 2016 15
  • Number of Products by Stage and Mechanism of Action, H2 2016 16
  • Number of Products by Stage and Route of Administration, H2 2016 17
  • Number of Products by Stage and Molecule Type, H2 2016 18
  • Pipeline by Amgen Inc., H2 2016 19
  • Pipeline by Millennium Pharmaceuticals Inc, H2 2016 20
  • Pipeline by ProNAi Therapeutics, Inc., H2 2016 21
  • Pipeline by SBI Biotech Co., Ltd., H2 2016 22
  • Dormant Projects, H2 2016 29
  • Discontinued Products, H2 2016 30

List of Figures

  • Number of Products under Development for, H2 2016 7
  • Number of Products under Development by Indication, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 10
  • Assessment by Monotherapy/Combination Products, H2 2016 15
  • Number of Products by Stage and Mechanism of Actions, H2 2016 16
  • Number of Products by Stage and Routes of Administration, H2 2016 17
  • Number of Products by Stage and Molecule Type, H2 2016 18
Back to Top